Drugs Made In America Acquisition Corp Rights
DMAAR
28 hedge funds and large institutions have $1.3M invested in Drugs Made In America Acquisition Corp Rights in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 9 closing their positions.
47% more capital invested
Capital invested by funds: $887K → $1.3M (+$415K)
20% less funds holding
Funds holding: 35 → 28 (-7)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGM
Alpine Global Management
New York
|
+$14.2K |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$11.4K |
| 3 |
DAM
DLD Asset Management
New York
|
+$2.58K |
| 4 |
TC
T3 Companies
New York
|
+$1.55K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$97.4K |
| 2 |
RC
RLH Capital
Great Neck,
New York
|
-$24.1K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$22.9K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$19.3K |
| 5 |
GCL
Glazer Capital LLC
New York
|
-$18K |
DMAAR Hedge Fund Activity: Q2 2026 in Review
28 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Rights (DMAAR) for Q2 2026, worth a combined $1.3M — up 47% from $887K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of DMAAR and 2 opened new positions — a net loss of 7 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was Alpine Global Management, adding an estimated $14.2K. The largest seller was Hudson Bay Capital Management, cutting an estimated $97.4K.
- 28 institutional investors held Drugs Made In America Acquisition Corp Rights (DMAAR) as of Q2 2026, down from 35 in Q1 2026.
- Funds reported $1.3M of Drugs Made In America Acquisition Corp Rights stock for Q2 2026, up 47% quarter-over-quarter.
- 2 funds opened new Drugs Made In America Acquisition Corp Rights positions in Q2 2026 and 9 closed out, a net change of -7 holders.
- The largest Drugs Made In America Acquisition Corp Rights buyer in Q2 2026 was Alpine Global Management, an estimated $14.2K added.
- The largest Drugs Made In America Acquisition Corp Rights seller in Q2 2026 was Hudson Bay Capital Management, an estimated $97.4K sold.
Based on aggregated 13F filings for Q2 2026.